Literature DB >> 24382686

Comorbidity of severe psychotic disorders with measures of substance use.

Sarah M Hartz1, Carlos N Pato2, Helena Medeiros2, Patricia Cavazos-Rehg1, Janet L Sobell2, James A Knowles2, Laura J Bierut1, Michele T Pato2.   

Abstract

IMPORTANCE: Although early mortality in severe psychiatric illness is linked to smoking and alcohol, to our knowledge, no studies have comprehensively characterized substance use behavior in severe psychotic illness. In particular, recent assessments of substance use in individuals with mental illness are based on population surveys that do not include individuals with severe psychotic illness.
OBJECTIVE: To compare substance use in individuals with severe psychotic illness with substance use in the general population. DESIGN, SETTING, AND PARTICIPANTS: We assessed comorbidity between substance use and severe psychotic disorders in the Genomic Psychiatry Cohort. The Genomic Psychiatry Cohort is a clinically assessed, multiethnic sample consisting of 9142 individuals with the diagnosis of schizophrenia, bipolar disorder with psychotic features, or schizoaffective disorder, and 10,195 population control individuals. MAIN OUTCOMES AND MEASURES: Smoking (smoked >100 cigarettes in a lifetime), heavy alcohol use (>4 drinks/day), heavy marijuana use (>21 times of marijuana use/year), and recreational drug use.
RESULTS: Relative to the general population, individuals with severe psychotic disorders have increased risks for smoking (odds ratio, 4.6; 95% CI, 4.3-4.9), heavy alcohol use (odds ratio, 4.0; 95% CI, 3.6-4.4), heavy marijuana use (odds ratio, 3.5; 95% CI, 3.2-3.7), and recreational drug use (odds ratio, 4.6; 95% CI, 4.3-5.0). All races/ethnicities (African American, Asian, European American, and Hispanic) and both sexes have greatly elevated risks for smoking and alcohol, marijuana, and drug use. Of specific concern, recent public health efforts that have successfully decreased smoking among individuals younger than age 30 years appear to have been ineffective among individuals with severe psychotic illness (interaction effect between age and severe mental illness on smoking initiation, P = 4.5 × 105). CONCLUSIONS AND RELEVANCE: In the largest assessment of substance use among individuals with severe psychotic illness to date, we found the odds of smoking and alcohol and other substance use to be dramatically higher than recent estimates of substance use in mild mental illness.

Entities:  

Mesh:

Year:  2014        PMID: 24382686      PMCID: PMC4060740          DOI: 10.1001/jamapsychiatry.2013.3726

Source DB:  PubMed          Journal:  JAMA Psychiatry        ISSN: 2168-622X            Impact factor:   21.596


  32 in total

1.  Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study.

Authors:  D A Regier; M E Farmer; D S Rae; B Z Locke; S J Keith; L L Judd; F K Goodwin
Journal:  JAMA       Date:  1990-11-21       Impact factor: 56.272

2.  Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Wai Tat Chiu; Olga Demler; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

Review 3.  Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective.

Authors:  H D Desai; J Seabolt; M W Jann
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

4.  Substance abuse among the chronic mentally ill.

Authors:  R E Drake; M A Wallach
Journal:  Hosp Community Psychiatry       Date:  1989-10

5.  Depressive symptoms and cigarette smoking among teens.

Authors:  E Goodman; J Capitman
Journal:  Pediatrics       Date:  2000-10       Impact factor: 7.124

6.  The co-occurrence of alcoholism with other psychiatric disorders in the general population and its impact on treatment.

Authors:  J E Helzer; T R Pryzbeck
Journal:  J Stud Alcohol       Date:  1988-05

7.  Depression in alcoholic schizophrenic patients.

Authors:  K T Brady; T Killeen; P Jarrell
Journal:  Am J Psychiatry       Date:  1993-08       Impact factor: 18.112

8.  Methodological issues in using a polydiagnostic approach to define psychotic illness.

Authors:  A E Farmer; S Wessely; D Castle; P McGuffin
Journal:  Br J Psychiatry       Date:  1992-12       Impact factor: 9.319

9.  Adult sequelae of adolescent depressive symptoms.

Authors:  D B Kandel; M Davies
Journal:  Arch Gen Psychiatry       Date:  1986-03

10.  Alcohol and cannabis use and mortality in people with schizophrenia and related psychotic disorders.

Authors:  Maju Mathew Koola; Robert P McMahon; Heidi J Wehring; Fang Liu; Kristen M Mackowick; Kimberly R Warren; Stephanie Feldman; Joo-Cheol Shim; Raymond C Love; Deanna L Kelly
Journal:  J Psychiatr Res       Date:  2012-05-16       Impact factor: 4.791

View more
  90 in total

1.  Association Between Substance Use Disorder and Polygenic Liability to Schizophrenia.

Authors:  Sarah M Hartz; Amy C Horton; Mary Oehlert; Caitlin E Carey; Arpana Agrawal; Ryan Bogdan; Li-Shiun Chen; Dana B Hancock; Eric O Johnson; Carlos N Pato; Michele T Pato; John P Rice; Laura J Bierut
Journal:  Biol Psychiatry       Date:  2017-06-06       Impact factor: 13.382

2.  Do timely mental health services reduce re-incarceration among prison releasees with severe mental illness?

Authors:  Marisa Elena Domino; Alex Gertner; Brigid Grabert; Gary S Cuddeback; Trenita Childers; Joseph P Morrissey
Journal:  Health Serv Res       Date:  2019-03-04       Impact factor: 3.402

3.  The Benefits of Genetic Addiction Risk Score (GARS) Testing in Substance Use Disorder (SUD).

Authors:  Kenneth Blum; Edward J Modestino; Marjorie Gondre-Lewis; Edwin J Chapman; Jennifer Neary; David Siwicki; David Baron; Mary Hauser; David E Smith; Alphonse Kenison Roy; Panayotis K Thanos; Bruce Steinberg; Thomas McLaughlin; Lyle Fried; Debmalya Barh; Georgia A Dunston; Rajendra D Badgaiyan
Journal:  Int J Genom Data Min       Date:  2018-01-15

4.  Prevalence and correlates of cannabis poisoning diagnosis in a national emergency department sample.

Authors:  Christopher P Salas-Wright; Jason T Carbone; Katherine J Holzer; Michael G Vaughn
Journal:  Drug Alcohol Depend       Date:  2019-09-18       Impact factor: 4.492

5.  An Online Drug Abuse Prevention Program for Adolescent Girls: Posttest and 1-Year Outcomes.

Authors:  Traci M Schwinn; Steven P Schinke; Jessica Hopkins; Bryan Keller; Xiang Liu
Journal:  J Youth Adolesc       Date:  2017-07-28

6.  Polygenic liability for schizophrenia predicts shifting-specific executive function deficits and tobacco use in a moderate drinking community sample.

Authors:  Alex P Miller; Ian R Gizer; William A Fleming Iii; Jacqueline M Otto; Joseph D Deak; Jorge S Martins; Bruce D Bartholow
Journal:  Psychiatry Res       Date:  2019-06-18       Impact factor: 3.222

7.  Redaction of Substance Abuse Claims in Medicare Research Files Affects Spending Outcomes for Nearly One in Five Beneficiaries with Serious Mental Illness.

Authors:  Pamela Roberto; Nicole Brandt; Eberechukwu Onukwugha; Bruce Stuart
Journal:  Health Serv Res       Date:  2016-07-24       Impact factor: 3.402

8.  Ideal Cardiovascular Health in Racially and Ethnically Diverse People with Serious Mental Illness.

Authors:  Mark R Hawes; Kimberly B Roth; Xiaoyan Wang; Ana Stefancic; Christopher Weatherly; Leopoldo J Cabassa
Journal:  J Health Care Poor Underserved       Date:  2020

9.  Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies.

Authors:  J Volavka; R A Van Dorn; L Citrome; R S Kahn; W W Fleischhacker; P Czobor
Journal:  Eur Psychiatry       Date:  2015-12-04       Impact factor: 5.361

10.  SorCS2 is required for BDNF-dependent plasticity in the hippocampus.

Authors:  S Glerup; U Bolcho; S Mølgaard; S Bøggild; C B Vaegter; A H Smith; J L Nieto-Gonzalez; P L Ovesen; L F Pedersen; A N Fjorback; M Kjolby; H Login; M M Holm; O M Andersen; J R Nyengaard; T E Willnow; K Jensen; A Nykjaer
Journal:  Mol Psychiatry       Date:  2016-07-26       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.